SMARCA4型
SMARCB1型
上皮样肉瘤
医学
肿瘤浸润淋巴细胞
癌症研究
肉瘤
免疫疗法
病理
染色质重塑
肿瘤科
免疫系统
免疫学
染色质
生物
DNA
遗传学
作者
Juan Martin‐Liberal,Elena Garralda,Jesús García-Donás,J.J. Soto Castillo,Alberto Mussetti,Carles Codony,Silvia Martin Lluesma,Susana Muñoz,Vladimir Galvao,Júlia Lostes,M. Rotxes,Cristina Prat‐Vidal,Jara Palomero,Ainhoa Muñoz,Rafael Moreno,Xavier García del Muro,Anna Sureda,Ramón Alemany,Alena Gros,Josep M. Piulats
出处
期刊:Future Oncology
[Future Medicine]
日期:2024-08-12
卷期号:20 (32): 2437-2445
标识
DOI:10.1080/14796694.2024.2385287
摘要
The SWI/SNF complex is a chromatin remodeling complex comprised by several proteins such as SMARCA4 or SMARCB1. Mutations in its components can lead to the development of aggressive rhabdoid tumors such as epithelioid sarcoma, malignant rhabdoid tumor or small cell carcinoma of the ovary hypercalcemic type, among others. These malignancies tend to affect young patients and their prognosis is poor given the lack of effective treatments. Characteristically, these tumors are highly infiltrated by TILs, suggesting that some lymphocytes are recognizing tumor antigens. The use of those TILs as a therapeutic strategy is a promising approach worth exploring. Here, we report the clinical protocol of the TILTS study, a Phase II clinical trial assessing personalized adoptive cell therapy with TILs in patients affected by these tumor types.
科研通智能强力驱动
Strongly Powered by AbleSci AI